Polysaccharide-based nanomedicines for cancer immunotherapy: a review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.13/4080 |
Resumo: | Cancer immunotherapy is an effective antitumor approach through activating immune systems to eradicate tumors by immunotherapeutics. However, direct administration of “naked” immunotherapeutic agents (such as nucleic acids, cytokines, adjuvants or antigens without delivery vehicles) often results in: (1) an unsatisfactory efficacy due to suboptimal pharmacokinetics; (2) strong toxic and side effects due to low targeting (or off-target) efficiency. To overcome these shortcomings, a series of polysaccharide-based nanoparticles have been developed to carry immunotherapeutics to enhance antitumor immune responses with reduced toxicity and side effects. Polysaccharides are a family of natural polymers that hold unique physicochemical and biological properties, as they could interact with immune system to stimulate an enhanced immune response. Their structures offer versatility in synthesizing multifunctional nanocomposites, which could be chemically modified to achieve high stability and bioavailability for delivering therapeutics into tumor tissues. This review aims to highlight recent advances in polysaccharide-based nanomedicines for cancer immunotherapy and propose new perspectives on the use of polysaccharide-based immunotherapeutics. |
id |
RCAP_9e0b332e4d4cf77e16b8c303b0f3e0df |
---|---|
oai_identifier_str |
oai:digituma.uma.pt:10400.13/4080 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Polysaccharide-based nanomedicines for cancer immunotherapy: a reviewPolysaccharidesDrug delivery systemsNanomedicinesCancer immunotherapyAnticancer efficacy.Faculdade de Ciências Exatas e da EngenhariaCancer immunotherapy is an effective antitumor approach through activating immune systems to eradicate tumors by immunotherapeutics. However, direct administration of “naked” immunotherapeutic agents (such as nucleic acids, cytokines, adjuvants or antigens without delivery vehicles) often results in: (1) an unsatisfactory efficacy due to suboptimal pharmacokinetics; (2) strong toxic and side effects due to low targeting (or off-target) efficiency. To overcome these shortcomings, a series of polysaccharide-based nanoparticles have been developed to carry immunotherapeutics to enhance antitumor immune responses with reduced toxicity and side effects. Polysaccharides are a family of natural polymers that hold unique physicochemical and biological properties, as they could interact with immune system to stimulate an enhanced immune response. Their structures offer versatility in synthesizing multifunctional nanocomposites, which could be chemically modified to achieve high stability and bioavailability for delivering therapeutics into tumor tissues. This review aims to highlight recent advances in polysaccharide-based nanomedicines for cancer immunotherapy and propose new perspectives on the use of polysaccharide-based immunotherapeutics.ElsevierDigitUMaZeng, YujunXiang, YufanSheng, RuilongTomás, HelenaRodrigues, JoãoGu, ZhongweiZhang, HuGong, QiyongLuo, Kui2022-02-15T09:05:56Z2021-01-01T00:00:00Z2021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.13/4080engZeng, Y., Xiang, Y., Sheng, R., Tomás, H., Rodrigues, J., Gu, Z., ... & Luo, K. (2021). Polysaccharide-based nanomedicines for cancer immunotherapy: a review. Bioactive Materials, 6(10), 3358-3382. https://doi.org/10.1016/j.bioactmat.2021.03.00810.1016/j.bioactmat.2021.03.008info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-05T12:57:14Zoai:digituma.uma.pt:10400.13/4080Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:07:54.289860Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
title |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
spellingShingle |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review Zeng, Yujun Polysaccharides Drug delivery systems Nanomedicines Cancer immunotherapy Anticancer efficacy . Faculdade de Ciências Exatas e da Engenharia |
title_short |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
title_full |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
title_fullStr |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
title_full_unstemmed |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
title_sort |
Polysaccharide-based nanomedicines for cancer immunotherapy: a review |
author |
Zeng, Yujun |
author_facet |
Zeng, Yujun Xiang, Yufan Sheng, Ruilong Tomás, Helena Rodrigues, João Gu, Zhongwei Zhang, Hu Gong, Qiyong Luo, Kui |
author_role |
author |
author2 |
Xiang, Yufan Sheng, Ruilong Tomás, Helena Rodrigues, João Gu, Zhongwei Zhang, Hu Gong, Qiyong Luo, Kui |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
DigitUMa |
dc.contributor.author.fl_str_mv |
Zeng, Yujun Xiang, Yufan Sheng, Ruilong Tomás, Helena Rodrigues, João Gu, Zhongwei Zhang, Hu Gong, Qiyong Luo, Kui |
dc.subject.por.fl_str_mv |
Polysaccharides Drug delivery systems Nanomedicines Cancer immunotherapy Anticancer efficacy . Faculdade de Ciências Exatas e da Engenharia |
topic |
Polysaccharides Drug delivery systems Nanomedicines Cancer immunotherapy Anticancer efficacy . Faculdade de Ciências Exatas e da Engenharia |
description |
Cancer immunotherapy is an effective antitumor approach through activating immune systems to eradicate tumors by immunotherapeutics. However, direct administration of “naked” immunotherapeutic agents (such as nucleic acids, cytokines, adjuvants or antigens without delivery vehicles) often results in: (1) an unsatisfactory efficacy due to suboptimal pharmacokinetics; (2) strong toxic and side effects due to low targeting (or off-target) efficiency. To overcome these shortcomings, a series of polysaccharide-based nanoparticles have been developed to carry immunotherapeutics to enhance antitumor immune responses with reduced toxicity and side effects. Polysaccharides are a family of natural polymers that hold unique physicochemical and biological properties, as they could interact with immune system to stimulate an enhanced immune response. Their structures offer versatility in synthesizing multifunctional nanocomposites, which could be chemically modified to achieve high stability and bioavailability for delivering therapeutics into tumor tissues. This review aims to highlight recent advances in polysaccharide-based nanomedicines for cancer immunotherapy and propose new perspectives on the use of polysaccharide-based immunotherapeutics. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-01T00:00:00Z 2021-01-01T00:00:00Z 2022-02-15T09:05:56Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.13/4080 |
url |
http://hdl.handle.net/10400.13/4080 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Zeng, Y., Xiang, Y., Sheng, R., Tomás, H., Rodrigues, J., Gu, Z., ... & Luo, K. (2021). Polysaccharide-based nanomedicines for cancer immunotherapy: a review. Bioactive Materials, 6(10), 3358-3382. https://doi.org/10.1016/j.bioactmat.2021.03.008 10.1016/j.bioactmat.2021.03.008 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129947517747200 |